Last Updated: 14 Nov 2024
Executive Summary
RAPT Therapeutics Inc. (RAPT) is a clinical-stage immunology-based biopharmaceutical company focused on developing oral small molecule therapies for unmet needs in oncology and inflammatory diseases. The company has a market capitalization of $62.15 million and trades on the NASDAQ exchange. The latest stock price is $1.57.
Company Overview
RAPT Therapeutics is headquartered in South San Francisco, California. The company's lead product candidate is FLX475, an oral small molecule inhibitor of the FLT3 receptor tyrosine kinase. FLX475 is currently in Phase 2 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia (AML). RAPT Therapeutics also has a pipeline of other preclinical and early-stage clinical programs targeting various oncology and inflammatory diseases.
Fundamental Analysis
RAPT Therapeutics is a pre-revenue company with no current earnings. The company's financial performance is expected to improve as its clinical programs progress and it begins to generate revenue from product sales.
The company's balance sheet is relatively weak, with total assets of $40.9 million and total liabilities of $107.7 million. RAPT Therapeutics has a negative EBITDA of $127.7 million and a net loss of $148.7 million for the trailing twelve months.
Technical Analysis
RAPT Therapeutics' stock price has been in a downtrend since early 2023. The stock is currently trading below its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is 30.2, which indicates that the stock is oversold.
Short Term Outlook
The short-term outlook for RAPT Therapeutics is mixed. The company's stock price is currently trading near its 52-week low. However, the stock's RSI is oversold, which could indicate that the stock is due for a rebound.
Long Term Outlook
The long-term outlook for RAPT Therapeutics is positive. The company's lead product candidate, FLX475, has the potential to be a blockbuster drug if it is approved for the treatment of AML. RAPT Therapeutics also has a pipeline of other promising preclinical and early-stage clinical programs.
Analyst Recommendations
The consensus analyst rating for RAPT Therapeutics is "Hold". The average analyst target price is $7.00.
Conclusion
RAPT Therapeutics is a pre-revenue company with a promising pipeline of clinical programs. The company's stock price is currently trading near its 52-week low, but the stock's RSI is oversold, which could indicate that the stock is due for a rebound. The long-term outlook for RAPT Therapeutics is positive.
